Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab added to atorvastatin in diabetic patients with hyperlipidemia or mixed dyslipidemia
2013-000723-14Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of evolocumab in hyperlipidemia and combined dyslipidaemia (4 arms), sponsored by Amgen. Primary endpoint: Co-primary efficacy endpoints. Started Jun 2015; status: completed.
02
Drugs
evolocumab
03
Conditions
hyperlipidemiacombined dyslipidaemia
Beyond the preview
Go deeper on 2013-000723-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000723-14.